Overview

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)

Status:
Not yet recruiting

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

This prospective, multi-centre, open label, non-randomised phase II trial aims restore radioiodine sensitivity in patients with NRAS or BRAFV600E mutant refractory thyroid cancer. Participants will be treated with Trametinib +/- Dabrafenib tyrosine kinase inhibitors for a period of 30 days, restoration of sensitivity will be monitored using 18F-FDG-PET & I-124 PET imaging.

Phase:

Phase 2

Details

Lead Sponsor:

Olivia Newton-John Cancer Research Institute

Collaborators:

Austin Health
Eastern Health
Monash Health
Peter MacCallum Cancer Centre, Australia
Royal Brisbane and Women's Hospital
Royal North Shore Hospital
Sir Charles Gairdner Hospital
The Alfred

Treatments:

Dabrafenib
Trametinib